Novo Nordisk A/S (NYSE:NVO) Shares Sold by Cerity Partners LLC

Cerity Partners LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 4.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 757,719 shares of the company's stock after selling 32,917 shares during the quarter. Cerity Partners LLC's holdings in Novo Nordisk A/S were worth $69,273,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Center for Financial Planning Inc. increased its holdings in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after buying an additional 123 shares during the last quarter. Albion Financial Group UT raised its holdings in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after purchasing an additional 278 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Novo Nordisk A/S by 82.1% in the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock valued at $46,000 after purchasing an additional 243 shares in the last quarter. Hager Investment Management Services LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $46,000. Finally, Halbert Hargrove Global Advisors LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $47,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 5.2 %

NYSE NVO traded up $3.18 during mid-day trading on Friday, reaching $64.39. 6,564,023 shares of the company's stock traded hands, compared to its average volume of 5,771,452. The company has a fifty day simple moving average of $78.23 and a 200-day simple moving average of $93.98. Novo Nordisk A/S has a 1-year low of $59.32 and a 1-year high of $148.15. The company has a market cap of $288.94 billion, a price-to-earnings ratio of 19.56, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were paid a $0.7874 dividend. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is 49.54%.

Analyst Ratings Changes

NVO has been the topic of a number of recent research reports. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a report on Monday, December 23rd. StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Monday. UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Three analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.